Table 2.

Phase I clinical trials of sapacitabine in solid tumors and hematologic malignancies.

Disease	Patients	Schedule	Recommended Phase II dose	Dose-limiting toxicity	Ref.
Advanced solid tumors	47	Daily × 5 days for 4 weeks	40 mg/m2/dose	Neutropenia	[18]
Advanced solid tumors	40	Days 1, 3 & 5, weekly for 4 weeks	160 mg/m2/dose	Myelosuppression	[19]
Relapsed acute leukemia & MDS	35	Twice a day for 7 days Every 3 – 4 weeks	325 mg/dose	Gastrointestinal	[22]
Relapsed acute leukemia & MDS	12	Twice daily for 3 days/week × 2 weeks	425 mg/dose	Gastrointestinal	[22]